6134-61-8

Basic information

• Product Name: 5-bromo-2-furamide
• Synonyms: 5-bromo-2-furamide;2-furancarboxamide, 5-bromo-;5-Bromo-2-furanamide;5-bromo-2-furamide(SALTDATA: FREE);5-broMo-furan-2-ylcarboxaMide;5-bromo-2-furancarboxamide;5-bromofuran-2-carboxamide;NSC32222
• CAS NO: 6134-61-8
• Molecular Formula: C₅H₄BrNO₂
• Molecular Weight: 190
• Mol File: 6134-61-8.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 264.5°C at 760 mmHg
• Flash Point: 113.8°C
• Appearance: /
• Density: 1.773g/cm³
• Vapor Pressure: 0.00966mmHg at 25°C
• Refractive Index: 1.57
• CAS DataBase Reference: 5-bromo-2-furamide(CAS DataBase Reference)
• NIST Chemistry Reference: 5-bromo-2-furamide(6134-61-8)
• EPA Substance Registry System: 5-bromo-2-furamide(6134-61-8)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 6134-61-8(Hazardous Substances Data)

Usage

General Description

5-bromo-2-furamide is an organic chemical compound with the molecular formula C4H3BrNO2. It is a derivative of furan and is commonly used as a precursor in the synthesis of various pharmaceuticals and agrochemicals. 5-bromo-2-furamide is also known for its use as an intermediate in the production of other organic compounds, and it is often employed as a reagent in chemical research and development. Its structure and properties make it an important building block in the field of organic chemistry, and its versatility and potential applications have made it a valuable compound in the pharmaceutical and agrochemical industries.

InChI:InChI=1/C5H4BrNO2/c6-4-2-1-3(9-4)5(7)8/h1-2H,(H2,7,8)

Upstream product

• 26726-16-9 5-bromofuran-2-carbonyl chloride 
• 585-70-6 5-bromo-furan-2-carboxylic acid 

Downstream Products

• 4915-06-4 5-bromofuran-2-carbonitrile 
• 1413063-98-5 acetic acid 2-(6-tert-butyl-8-fluoro-1-oxo-1H-phthalazin-2-yl)-6-(5-carbamoyl-furan-2-yl)-benzyl ester 
• 57753-81-8 5-(4-chlorophenyl)furan-2-carboxamide 

Relevant articles and documents

Structure-Guided Modification of Heterocyclic Antagonists of the P2Y14 Receptor

The P2Y14 receptor (P2Y14R) mediates inflammatory activity by activating neutrophil motility, but few classes of antagonists are known. We have explored the structure-activity relationship of a 3-(4-phenyl-1H-1,2,3-triazol-1-yl)-5-(aryl)benzoic acid antagonist scaffold, assisted by docking and molecular dynamics (MD) simulation at a P2Y14R homology model. A computational pipeline using the High Throughput MD Python environment guided the analogue design. Selection of candidates was based upon ligand-protein shape and complementarity and the persistence of ligand-protein interactions over time. Predictions of a favorable substitution of a 5-phenyl group with thiophene and an insertion of a three-methylene spacer between the 5-aromatic and alkyl amino moieties were largely consistent with empirical results. The substitution of a key carboxylate group on the core phenyl ring with tetrazole or truncation of the 5-aryl group reduced affinity. The most potent antagonists, using a fluorescent assay, were a primary 3-aminopropyl congener 20 (MRS4458) and phenyl p-carboxamide 30 (MRS4478).

T-BuXPhos: A highly efficient ligand for Buchwald-Hartwig coupling in water

An efficient and versatile 'green' catalytic system for the Buchwald-Hartwig cross-coupling reaction in water is reported. In an aqueous micellar medium, the combination of t-BuXPhos with [(cinnamyl)PdCl]2 showed excellent performance for coupling arylbromides or chlorides with a large set of amines, amides, ureas and carbamates. The method is functional-group tolerant, proceeds smoothly (30 to 50 °C) and provides rapid access to the target compounds in good to excellent isolated yields. When applied to the synthesis of a known NaV1.8 modulator, this method led to a significant improvement of the E-factor in comparison with classical organic synthesis. the Partner Organisations 2014.

BENZIMIDAZOLE CANNABINOID AGONISTS BEARING A SUBSTITUTED HETEROCYCLIC GROUP

The present invention is related to novel benzimidazole compounds of formula (I) having cannabinoid receptor agonistic properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals, in particular humans.